The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Fresenius Medical Care AG's 14-Day RSI or its related term are showing as below:
CHIX:FMEd's 14-Day RSI is ranked worse than 71.78% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 50.425
vs CHIX:FMEd: 56.80
Fresenius Medical Care AG (CHIX:FMEd) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Fresenius Medical Care AG 14-Day RSI Related Terms
CHIX:FMED vs HCA, THC, DVA: 14-Day RSI Comparison
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's 14-Day RSI falls into.
Fresenius Medical Care AG (CHIX:FMEd) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG (CHIX:FMED) has a 14-Day RSI of 56.80 as of Jul. 06, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fresenius Medical Care AG and its competitors. According to the industry distribution chart, Fresenius Medical Care AG ranks #501 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 71.8%.
Is Fresenius Medical Care AG's 14-Day RSI too high?
Fresenius Medical Care AG's current 14-Day RSI is 56.80. The Healthcare Providers & Services industry median 14-Day RSI is 50.43. Fresenius Medical Care AG's value of 56.80 is 12.6% above this industry median. Based on the distribution chart, Fresenius Medical Care AG ranks #501 out of 698 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius Medical Care AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's 14-Day RSI compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #501 out of 698 companies for 14-Day RSI. This places Fresenius Medical Care AG in the lower half of its industry. The industry median 14-Day RSI is 50.43. Fresenius Medical Care AG's value of 56.80 is 12.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 50.43, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius Medical Care AG's current 14-Day RSI of 56.80 is 12.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Fresenius Medical Care AG and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 50.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius Medical Care AG's current 14-Day RSI is 56.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (CHIX:FMED) is currently considered Fairly Valued. The stock's GF Value™ is €41.35, compared to a current price of €40.03 — trading 3.2% below its estimated fair value. The current 14-Day RSI is 56.80 and 12.6% above the Healthcare Providers & Services industry median of 50.43. Fresenius Medical Care AG's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Fresenius Medical Care AG (CHIX:FMED), the current 14-Day RSI is 56.80 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (CHIX:FMED) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be undervalued.
The current stock price of €40.03 is trading 3.2% below its estimated GF Value™ of €41.35.
GuruFocus considers Fresenius Medical Care AG to be Fairly Valued.
Key valuation signals for CHIX:FMED:
14-Day RSI: 56.80
GF Value™: €41.35 vs. price of €40.03 (3.2% below fair value)
Industry Position: 12.6% above the Healthcare Providers & Services median (#501 of 698)
No single metric tells the full story. See the CHIX:FMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
69GF Score
Get the complete analysis for CHIX:FMED
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FMED has been successfully added to your 